Distinguished in Mast Cell Activation Syndrome (MCAS)

Luigi Scaffidi

Policlinico G.B.ROSSI AOUI Verona
Verona, IT 
Distinguished in Mast Cell Activation Syndrome (MCAS)
Policlinico G.B.ROSSI AOUI Verona
Verona, IT 
OverviewLocationsClinical Research

Overview

Luigi Scaffidi practices in Verona, Italy. Mr. Scaffidi is rated as a Distinguished expert by MediFind in the treatment of Mast Cell Activation Syndrome (MCAS). His top areas of expertise are Myelofibrosis, Chronic Myelogenous Leukemia (CML), Mast Cell Activation Syndrome (MCAS), and Splenomegaly.

His clinical research consists of co-authoring 54 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 10 articles in the study of Mast Cell Activation Syndrome (MCAS).

Gender
Male

Locations

Policlinico G.B.Rossi AOUI Verona
Verona, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Myeloproliferative Neoplasms (MPN) and COVID-19
Myeloproliferative Neoplasms (MPN) and COVID-19
Enrollment Status: Completed
Publish Date: September 15, 2025
The Benefit/Risk Profile of Pegylated Proline-Interferon Alpha-2b (AOP2014) Added to the Best Available Strategy Based on Phlebotomies in Low-risk Patients With Polycythemia Vera (PV). The Low-PV Randomized Trial
The Benefit/Risk Profile of Pegylated Proline-Interferon Alpha-2b (AOP2014) Added to the Best Available Strategy Based on Phlebotomies in Low-risk Patients With Polycythemia Vera (PV). The Low-PV Randomized Trial
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug, Procedure
Study Drugs: AOP2014, Acetylsalicylic acid
Study Phase: Phase 2
Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid Leukemia: a Prospective Study Comparing Nilotinib Versus Imatinib With Switch to Nilotinib in Absence of Optimal Response. SUSTRENIM Study - GIMEMA CLM1415
Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid Leukemia: a Prospective Study Comparing Nilotinib Versus Imatinib With Switch to Nilotinib in Absence of Optimal Response. SUSTRENIM Study - GIMEMA CLM1415
Enrollment Status: Unknown
Publish Date: January 20, 2022
Intervention Type: Drug
Study Drugs: Imatinib, Nilotinib
Study Phase: Phase 4
Use of Direct Oral Anticoagulants (DOACs) in Patients With Ph-negative Myeloproliferative Neoplasms
Use of Direct Oral Anticoagulants (DOACs) in Patients With Ph-negative Myeloproliferative Neoplasms
Enrollment Status: Completed
Publish Date: February 21, 2021
Intervention Type: Drug
Secondary Cancers in Myeloproliferative Neoplasms (MPN-K Study)
Secondary Cancers in Myeloproliferative Neoplasms (MPN-K Study)
Enrollment Status: Completed
Publish Date: December 06, 2019
Intervention Type: Other
View 4 Less Clinical Trials

54 Total Publications

Digital PCR (dPCR) is able to anticipate the achievement of stable deep molecular response in adult chronic myeloid leukemia patients: results of the DEMONSTRATE study.
Digital PCR (dPCR) is able to anticipate the achievement of stable deep molecular response in adult chronic myeloid leukemia patients: results of the DEMONSTRATE study.
Journal: Annals of hematology
Published: September 12, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Scaffidi's expertise for a condition
ConditionClose
    View All 7 Distinguished Conditions
    View All 7 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile